DayFR Euro

Covid-19: Didier Raoult’s study on hydroxychloroquine is officially invalidated: News

The journal which published the study on the use of hydroxychloroquine against Covid-19 retracted it for non-compliance with scientific ethics, four years after its publication, reveals L’Express.

This study made him famous worldwide. The study on the use of hydroxychloroquine as a treatment for Covid-19, carried out by the Institut Hospitalo-Universitaire (IHU) of and co-written by Professor Didier Raoult, was officially invalidated on Tuesday September 17, reveals L’Express. The International Journal of Antimicrobial Agents, which published the results in March 2020, retracted the study after four years of controversy. In question? A methodology considered dubious and biased results.

“Concerns have been raised regarding this article, relating to compliance with Elsevier’s publication ethics policies and the appropriate conduct of research involving human participants, as well as concerns raised by three of the authors themselves regarding the methodology and conclusions of the article”said the publisher of the magazine in a press release.

Call to question all the work carried out by Didier Raoult

An investigation was thus carried out by “un expert impartial”, during 2024. This highlights in particular “non-compliance with French research law”, “failure to obtain informed consent from patients”, “the addition of a medication not provided for in the research protocol” or even “results manipulated and misinterpreted”.

These damning conclusions come after the retirement of Professor Didier Raoult, who has already been banned from practicing medicine for two years, last October. The French Society of Pharmacology and Therapeutics congratulated “this late, but essential, recognition of scientific excesses”. The SFPT now calls for a re-study and questioning of all the work carried out under the leadership of Professor Didier Raoult.

published on December 17 at 2:28 p.m., Emma Allamand, 6Medias

Share

Coronavirus

-

Related News :